Licensed pharmacies cannot legally compound BPC-157 for human use
On February 27, 2026, HHS Secretary Kennedy announced that approximately 14 of the 19 peptides previously classified as Category 2 restricted including BPC-157, TB-500, CJC-1295, ipamorelin, and sermorelin are expected to return to Category 1 status, meaning they can again be legally compounded by 503A and 503B pharmacies
ERN1 was associated with efavirenz- related DILI (OR, 18.2), and DRB1*16:01-DQB1*05:02 was associated with the nonopioid analgesic flupirtine (OR, 18.7)
In recent years, peptide therapy has surged in popularity among men in New York City , driven by growing interest in non-invasive solutions for performance, recovery, and longevity
Clinical Differentiation Between Neurogenic and Vascular Claudication Imaging Most patients presenting with lumbar spinal stenosis are older than 50 years